Chronic Lymphocytic Leukemia Therapeutics Market is Expanding Rapidly With Top Players: F. Hoffmann-La Roche Ltd, Novartis International AG, GlaxoSmithKline
Request Here Sample of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2049
Increasing prevalence of leukemia is expected to drive growth of the global chronic lymphocytic leukemia therapeutics market during the forecast period. According to the American Society of Clinical Oncology (ASCO), chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults aged 19 years and above with 37% of cases. According to the same source, around 21,040 new cases and 4,060 deaths are expected to occur in 2020 due to CLL in the U.S.
Furthermore, according to the Leukemia & Lymphoma Society (LLC), in 2020, around 60,530 people are expected to be diagnosed with leukemia in the U.S. Such a high prevalence of CLL and leukemia has increased the demand for necessary therapeutics such as chemotherapy. Thus, these factors are expected to drive growth of the global chronic lymphocytic leukemia therapeutics market during the forecast period. Moreover, increasing geriatric population is expected to boost the global chronic lymphocytic leukemia therapeutics market growth over the forecast period.
Key Players of Chronic Lymphocytic Leukemia Therapeutics Market:
The key Chronic Lymphocytic Leukemia Therapeutics industry leaders profiled in the report include F. Hoffmann-La Roche Ltd, Novartis International AG, GlaxoSmithKline Pharmaceuticals Limited, Celgene Corporation, Genmab A/S, Abbvie Inc. Teva Pharmaceutical Industries Ltd., Biogen Idec, AstraZeneca plc, Arno Therapeutics, Genzyme Corporation, Gilead Sciences INC., and others.. These key players have adopted strategies, such as product portfolio expansion, mergers & acquisitions, agreements, geographical expansion, and collaborations, to enhance their market penetration
Get Sample PDF Brochure@ https://www.coherentmarketinsights.com/insight/request-pdf/2049
Chronic Lymphocytic Leukemia Therapeutics Market Segmentation
Based on type, the absolute Chronic Lymphocytic Leukemia Therapeuticss segment contributed to the largest share in 2020, accounting for more than two-fifths of the total share, and is estimated to maintain its dominant position during the forecast period.
Bendamustine Hydrochloride (Treanda)
By Distribution Channel
Chronic Lymphocytic Leukemia Therapeutics Market regional analysis includes:
Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia and Australia)
Europe (Turkey, Germany, Russia, United Kingdom, Italy, France, etc.)
North America (United States, Mexico and Canada).
South America (Brazil etc.)
Middle East and Africa (GCC countries and Egypt).
In the market segmentation by manufacturers, the report covers the following companies: F. Hoffmann-La Roche Ltd, Novartis International AG, GlaxoSmithKline Pharmaceuticals Limited, Celgene Corporation, Genmab A/S, Abbvie Inc. Teva Pharmaceutical Industries Ltd., Biogen Idec, AstraZeneca plc, Arno Therapeutics, Genzyme Corporation, Gilead Sciences INC., and others.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Exclusive offer!!! Purchase the report at a discounted rate!!!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Buy Now with Discount for Premium Report : https://www.coherentmarketinsights.com/promo/buynow/2049
Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.
Note – In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.
(*If you have any special requirements, please let us know and we will offer you the report as you want.)
Coherent Market Insights 1001 4th Ave,
#3200 Seattle, WA 98154,U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
Coherent Market Insights' market intelligence service provides a comprehensive view of the market, using the existing sources of information. Our market intelligence service addresses key challenges of a market; helps in finding opportunities across various industries, and helps potential investors and partners to support the strategic decision-making process.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Lymphocytic Leukemia Therapeutics Market is Expanding Rapidly With Top Players: F. Hoffmann-La Roche Ltd, Novartis International AG, GlaxoSmithKline here
News-ID: 2313070 • Views: 302
More Releases from Coherent Market Insights
The Emergence of COVID-19 to Augment the Growth of the Vaccine Adjuvant Market
According to the Centers for Disease Control and Prevention (CDC), adjuvant is an ingredient used in vaccines that helps create a stronger immune response in people receiving the vaccine. In other words, adjuvants help vaccines work better. Growth of the vaccine adjuvant market is mainly driven by the outbreak of COVID-19 (the global pandemic). The use of an adjuvant is of importance in a pandemic where there is significant demand
Cascades Inc. Launched Cascades Fluff and Tuff Toilet Papers and Paper Towels fo …
Growing demand for sanitation and hygiene products such as tissue products used in the food service and healthcare industry is fostering the growth of the tissue products market. Also, advancement in tissue manufacturing technology such as ADT, ATMOS, and NTT is again uplifting the growth of the market. For instance, in September 2017, Sofidel Group launched Papernet BioTech, a toilet paper with Biologic Active Tissue Paper technology. The non-pathogenic microorganisms
North America Is Projected To Hold a Dominant Position in the Global Peptide Syn …
The growing prevalence of infectious diseases is fostering the growth of the peptide synthesis market. For instance, according to an article published by the Centers for Disease Control and Prevention (CDC) in February 2020, reports that the number of visits with infectious and parasitic diseases to physician offices as the primary diagnosis was 15.5 million in 2016 in the U.S. Moreover, key players are adopting inorganic strategies such as collaborations
Bioivt Acquired Ascendance Biotechnology to Expand Its Presence in Organ-On-A-Ch …
Growing lung-based organ culture and increasing application in disease modeling, phenotypic screening, and patient stratification is expanding organ-on-a-chip market size. This device offers better clinical examinations compared to Petri dishes and animal testing, thus helping scientists and companies a better understanding regarding the functioning of internal organs such as lungs and brains. Moreover, increasing funding and initiatives by the government are again expected to foster the growth of the organ-on-a-chip
More Releases for Therapeutics
Dravet Syndrome Therapeutics- Pipeline Analysis 2018 | Zogenix, Inc., Ovid Thera …
Dravet syndrome is a form of severe myoclonic epilepsy that occurs in infants during their first year of age. If left untreated, it can be associated with other types of seizures, and status epilepticus. Children having Dravet syndrome are generally observed with poor cognitive skills and hyperactivity. Download the sample report @ https://www.pharmaproff.com/request-sample/1098 It severely affects the person’s quality of life and around 10-20% of the patient are estimated to die due
Pontine Glioma Therapeutics- Pipeline Analysis 2018 | Y-mAbs Therapeutics, Inc.
Pontine glioma is a malignant tumour which develops from the brain stem cells. Based on the grade of growth, it is categorized into anaplastic astrocytomas and glioblastoma multiforme (GBM). Download the sample report @ https://www.pharmaproff.com/request-sample/1117 Pontine glioma is more prevalent in children than adults. The common signs and symptoms of pontine glioma are squints, swallowing problems, slurred speech, facial weakness, abnormal gait, difficulty in writing and changes in personality and behaviour.
Rheumatology Therapeutics Market
Global Rheumatology Therapeutics Market: Snapshot A rising elderly population and increasing allocations for research and development of new drugs is what is serving to drive growth in the global rheumatology therapeutics market. This has led to the emergence of many new drugs. Their swift approvals by the appropriate authorities has also led to the growth in the market. A report by Transparency Market Research uncovers after in-depth study that the global rheumatology
STORM Therapeutics Joins SMi’s 9th Annual RNA Therapeutics
SMi are delighted to welcome Oliver Rausch, VP Research & Development, Storm Therapeutics, onto the speaker line-up for day 1 at RNA Therapeutics 2018! Oliver has overall responsibility for developing STORM’s target discovery platform and for the delivery of small molecule drugs from its emerging drug discovery pipeline. Oliver worked closely with scientific founders Professors Tony Kouzarides and Eric Miska to secure the initial £12m series; an investment that launched STORM
Bone Degeneration Therapeutics Market
Bone degeneration is characterized by deterioration of articular cartilage covering the joints. Cartilage aids free movement of the joint without any resistance. Reduction in flexibility of the joint due to deterioration of cartilage leads to inflammation, compressed nerves, and pain. Aging is one of the natural causes of bone degeneration, which is also fueled by several conditions such as injuries, congenital disorders, diabetes, and obesity. Symptoms of degenerative bone disorders
Global Dyslipidemia Therapeutics Market
Dyslipidemia is one of the metabolic disorder, which is described by unbalanced level and thickness of lipoproteins and triglycerides. The disorder also includes protein deficiency and over production. These disorders can be caused by increase in the serum total cholesterol, triglyceride concentrations, and low-density lipoprotein (LDL) cholesterol, and a decrease in the high-density lipoprotein (HDL) cholesterol concentration. These condition are mainly associated with cardiovascular or coronary heart disease. The other